As a marker of minimal residual disease in B-cell acute lymphoblastic leukemia (B-ALL), CD58 has been reported in B-ALL at diagnosis and short-term follow-ups after standard chemotherapies. However, ...

The potential impact of this form of therapy in pediatric precursor B-lineage acute lymphoblastic leukemia (pre-B ALL) has yet to be determined. Mabs directed against the cell surface antigens ...

Search for other works by this author on: ...

University of California Davis School of Medicine, Sacramento, CA.

The work is published in the journal Biomarker Research. B-cell acute lymphoblastic leukemia (B-ALL) is a life-threatening and highly aggressive form of blood cancer. It is the most common ...

SAN DIEGO -- Children with newly diagnosed B-cell acute lymphoblastic leukemia (B-ALL) lived significantly longer without disease recurrence when they received the bispecific T-cell engager ...

BREVARD COUNTY, FLORIDA – Sunday, April 27, 2025, at 1 p.m., the American Legion Post 200, 105 Ocean Blvd., Satellite Beach, ...

Autolus Therapeutics (AUTL) confirmed that the U.K. Medicines and Healthcare products Regulatory Agency has granted ...

As with all products, the MHRA will keep its safety under close review. The Medicines and Healthcare products Regulatory ...